Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Antoîne Italiano(Institut Bergonié), Jean‐Charles Soria, Maud Toulmonde(Institut Bergonié), Jean‐Marie Michot(Institut Gustave Roussy), Carlo Lucchesi(Institut Bergonié), Andréa Varga(Institut Gustave Roussy), Jean‐Michel Coindre(Université de Bordeaux), Stephen J. Blakemore(Epizyme (United States)), Alicia Clawson(Epizyme (United States)), Benjamin Suttle(Epizyme (United States)), Alice McDonald(Epizyme (United States)), Mark Woodruff(Epizyme (United States)), Scott Ribich(Epizyme (United States)), Eric Hedrick(Epizyme (United States)), Heike Keilhack(Epizyme (United States)), Blythe Thomson(Epizyme (United States)), Takashi Owa(Eisai (United States)), Robert A. Copeland(Epizyme (United States)), Peter Ho(Epizyme (United States)), Vincent Ribrag(Institut Gustave Roussy)
Cited by 614
Abstract
Related Papers
No related papers found
Powered by citation graph analysis